As a beacon of hope for patients in Georgia, an executive director has finally been appointed by the Access to Medical Cannabis Commission to oversee the next stages of development for the state’s medical marijuana program.
Andrew Turnage, who has experience as executive director for both the Georgia State Board of Cosmetology and Barbers and the Georgia Board of Nursing, was selected over four other applicants.
“We have one goal, and that’s to get oil for families in need,” Turnage said to Valdosta Today. “Think about families that have struggled to have their basic needs met during this pandemic. We have families in Georgia that have struggled for years to get this basic need, low-THC oil, and our task will be to ensure that they receive it.”
Turnage came highly recommended for the position by The Goodwin Group, an executive recruiting firm that reportedly consulted with cannabis industry experts before making the recommendation.
“Mr. Turnage not only has the experience The Goodwin Group recommended, but specifically in the area of state licensing, which is essential to getting us up and running and producing low-THC oil,” said the commission’s chairman and principal surgeon at the Atlanta Neurological & Spine Institute, Dr. Christopher Edwards.
Turnage will be responsible for establishing the selection process for licensing cultivation and distribution businesses as well as lab-testing and system regulations. At least six cultivation licenses are expected to be awarded, but the timeline for when the legal distribution system is expected to be in place has not been released.
According to the program’s website, conditions that qualify a person to be able to apply for the Georgia Medical Marijuana Program include:
- Cancer, when such diagnosis is end stage or the treatment produces related wasting illness or recalcitrant nausea and vomiting
- Amyotrophic lateral sclerosis, when such diagnosis is severe or end stage
- Seizure disorders related to diagnosis of epilepsy or trauma related head injuries
- Multiple sclerosis, when such diagnosis is severe or end stage
- Crohn’s disease
- Mitochondrial disease
- Parkinson’s disease, when such diagnosis is severe or end stage
- Sickle cell disease, when such diagnosis is severe or end stage
- Tourette’s syndrome, when such syndrome is diagnosed as severe
- Autism spectrum disorder, when (a) patient is 18 years of age or more, or (b) patient is less than 18 years of age and diagnosed with severe autism
- Epidermolysis bullosa
- Alzheimer’s disease, when such disease is severe or end stage
- AIDS when such syndrome is severe or end stage
- Peripheral neuropathy, when symptoms are severe or end stage
- Patient is in hospice program, either as inpatient or outpatient
- Intractable pain
- Post-traumatic stress disorder resulting from direct exposure to or witnessing of a trauma for a patient who is at least 18 years of age
A Brief History
It all began in 2015 when Georgia lawmakers approved legislation to allow registered medical marijuana patients in the state to possess and use up to 20 fluid ounces of low-THC cannabis oil. In order to qualify as “low-THC” the oil must contain no more than 5 percent of the psychoactive cannabinoid, tetrahydrocannabinol (THC).
Last year, the state appointed members to the Georgia Access to Medical Cannabis Commission, and an executive director was just elected by that board in May of 2020.
In five years of program development, patients still have no way to legally purchase the oil within state lines. Registered patients and caregivers are forced to obtain the medicine on the black market, where it is neither regulated nor lab-tested, or buy it in another state, breaking federal laws to drive it across state lines.
Georgia legislators have been aware all along that a system for distribution needed to be established. In 2017, a top Georgia lawmaker even made headlines when he admitted to smuggling medical marijuana into the state for patients who were suffering.
The chemical compounds found in the cannabis plant that translate into the effects felt, and deliver medicinal value to the consumer, are called cannabinoids. Cannabinoids, like tetrahydrocannabinol (THC) and cannabidiol (CBD), work synergistically in a process known as the entourage effect. Simply put, this means that these cannabinoids are more effective when they are able to work as a team than when they are used separately. This is why many proponents insist that whole plant medicine or full spectrum cannabis oils are more effective treatment options than CBD oil that contains 5 percent or less THC. For many patients, low-THC oil and CBD isolates simply are not enough to treat debilitating symptoms.
Now that Georgia is one step closer to providing patients with safe, reliable access to medical cannabis oil, many hope the next step will be expanding the law to include different forms, more methods of delivery, and higher potency options.